ACSS2 is highly expressed in several cancers, including breast cancer, and ACSS2 inhibitors have been proposed to treat cancers in a patent by a drug discovery company, Metabomed Ltd., based in Yavne, Israel [60], with promising potential in the application to clinical practice. Here, ACSS2 is linked to breast carcinoma.